Cannigistics Agri-Solutions Enters MOU for Clinical Trials Software Platform

Calyx Bio-Ventures Inc. (TSXV:CYX) announced that Cannigistics Agri-Solutions Corp., its subsidiary, has entered into a memorandum of understanding (MOU) regarding the implementation of a clinical trials software platform.

As quoted in the press release:

The MOU has been signed with a well respected group of Canadian medical specialists that require a secure platform to gather, store, analyze, and report on the results of the trials. The Cannigistics’ software and information technology platform will be utilized to create an environment that will allow the physicians to conduct the trials with confidence. Data can be used, parsed, sorted, analyzed and made anonymous so that other specialists can also have access to the results with no concerns over patient confidentiality.

The resulting platform will be a tailor made solution licensed on a non-exclusive basis, allowing Cannigistics to license the resulting platform to any other parties conducting clinical trials with the ability to customize to their specific needs. This will be a new area of deployment for the Cannigistics software platform, and potentially opens up a new market in the near term.

Roger Forde, president and CEO of Cannigistics, commented:

We are pleased to have entered into an agreement with a respected group of healthcare practitioners to provide an end-to-end technical solution, from application design to deployment and management. This further validates the strategy that Cannigistics has established to provide technology solutions addressing key requirements of companies operating in the health sciences sector. We are looking forward to becoming a significant participant in the sector.

Click here to read the full Calyx Bio-Ventures Inc. (TSXV:CYX) press release. marketwired